VERTEX PHARMACEUTICALS INC / MA Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows, 16 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-03-31: Reporting owner MCGLYNN MARGARET G; Form 4; Security Common Stock (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2021-02-05: Reporting owner Parini Michael; Form 4; Security Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-08-19: Reporting owner ALTSHULER DAVID; Form 4; Security Common Stock (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-04-05: Reporting owner Chodakewitz Jeffrey; Form 4; Security Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
VRTX insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | MCGLYNN MARGARET G Director | 4 | Common Stock (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 10,000 owned after | $127.54 | $260.97 | 2022-04-04 |
| 2021-02-05 | Parini Michael Officer (EVP, Chief Adm, Leg & BD Off) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,930 0 owned after | $86.52 exercise price | $215.26 | 2021-02-09 |
| 2019-08-19 | ALTSHULER DAVID Officer (EVP, Global Research and CSO) | 4 | Common Stock (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +4,659 13,980 owned after | $86.52 exercise price | $187.09 | 2019-08-20 |
| 2017-04-05 | Chodakewitz Jeffrey Officer (EVP GMDA, CMO) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,021 10,313 owned after | $73.51 exercise price | $114.11 | 2017-04-07 |
| 2017-02-03 | Sachdev Amit Officer (EVP, CRO) | 4 | Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,065 31,065 owned after | $86.52 exercise price | $86.73 | 2017-02-07 |
| 2016-02-02 | Chodakewitz Jeffrey Officer (EVP GMDA, CMO) | 4 | Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,735 28,735 owned after | $91.05 exercise price | $90.98 | 2016-02-04 |
| 2007-01-03 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −125 56,335 owned after | $9.69 exercise price | $36.90 | 2007-01-04 |
| 2006-12-26 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −125 56,460 owned after | $9.69 exercise price | $37.18 | 2006-12-27 |
| 2006-12-18 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −125 56,585 owned after | $9.69 exercise price | $38.56 | 2006-12-19 |
| 2006-12-11 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250 56,710 owned after | $9.69 exercise price | $41.14 | 2006-12-12 |
| 2006-12-04 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −72 57,138 owned after | $9.07 exercise price | $44.19 | 2006-12-05 |
| 2006-12-04 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −178 56,960 owned after | $9.69 exercise price | $44.19 | 2006-12-05 |
| 2006-11-27 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250 57,210 owned after | $9.07 exercise price | $42.95 | 2006-11-28 |
| 2006-11-20 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250 57,460 owned after | $11.18 exercise price | $45.12 | 2006-11-21 |
| 2006-11-13 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250 57,710 owned after | $11.18 exercise price | $42.48 | 2006-11-14 |
| 2006-11-09 | POWER JOHANNA MESSINA Officer (VP & Controller) | 4 | Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −250 57,960 owned after | $11.18 exercise price | $41.14 | 2006-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |